Results 151 to 160 of about 4,485 (189)

Beyond Antiretroviral Therapy: Molecular and Immunological Innovations in HIV Treatment. [PDF]

Trop Med Infect Dis
Alanazi A, Ibrahim MN, Elithy MA.
europepmc   +1 more source

Ex vivo-expanded allogeneic Vδ2 T cells specifically reduce reservoirs of HIV-1 following latency reversal. [PDF]

JCI Insight
Mann BT, Sanz M, Chitrakar A, Langlands K, Siegel M, Soriano-Sarabia N.   +5 more
europepmc   +1 more source

World free HIV: the novel therapeutic approaches for eliminating latent HIV infection. [PDF]

Virol J
Zubair A, Bibi B, Alkahtani AM, Shahani MY, Afghan N.   +4 more
europepmc   +1 more source

Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa. [PDF]

Front Immunol
Kankundiye P, Kia P, Kankaka E, Nabatanzi R, Mahmoudi T, Nakanjako D.   +5 more
europepmc   +1 more source

The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir. [PDF]

PLoS Pathog
Kim Y, Anderson JL, Tumpach C, Solomon A, Ong J, Tanaka K, Zerbato JM, Tan T, Teh CE, Gray DHD, Arandjelovic P, McMahon J, Meagher N, Price D, Pellegrini M, Roche M, Lewin SR.   +16 more
europepmc   +1 more source

Block-and-Lock Approaches for HIV Cure: Mechanistic Insights, Challenges, and Emerging Role of CPSF6. [PDF]

Int J Mol Sci
Tolomeo M, Cascio A.
europepmc   +1 more source

Inflammation and RONS Dysregulation by Redox Enzymes as Mechanistic Links in HIV-1-Cancer Comorbidity. [PDF]

Pathogens
Ang CG, Eyunni S, Chaiken IM.
europepmc   +1 more source

Harziachalasins A-G, polycyclic-fused cytochalasins from the endophytic fungus Trichoderma harzianum MLJ-4 with HIV latency reversal activity. [PDF]

Nat Prod Bioprospect
Zhang YJ, Yang XY, Fu YF, Liao Q, Chen JQ, Chen XA, Huang D, Yuan T, Chen X, Yin S, Tang GH.   +10 more
europepmc   +1 more source

Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation. [PDF]

J Virol
Stern J, Shepherd RA, Kim Y, Tumpach C, Amos KE, Williams OHL, Varshney S, King HAD, Rhodes A, Lewin SR, Roche M.   +10 more
europepmc   +1 more source

Solving a BAF'ling Problem : pharmacological Reversal of HIV-1 Latency

, 2019
openaire   +1 more source